• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by AstraZeneca

    < Previous 1 2 3 4 5 6 7 Next >
    AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    FLUMIST approved for self-administration in the US
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) plus IMJUDO® (tremelimumab-actl) demonstrated unprecedented overall survival in advanced liver cancer with one in five patients surviving five years in HIMALAYA Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) perioperative regimen reduced the risk of recurrence by 32% and the risk of death by 25% vs. neoadjuvant chemotherapy alone in muscle-invasive bladder cancer in the NIAGARA Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) showed substantial clinical activity in patients with HER2-positive metastatic breast cancer and brain metastases
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Novel computational pathology-based TROP2 biomarker for datopotamab deruxtecan was predictive of clinical outcomes in patients with non-small cell lung cancer in TROPION-Lung01 Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) approved in the US for the treatment of resectable non-small cell lung cancer before and after surgery
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) granted Priority Review and Breakthrough Therapy Designation for patients with limited-stage small cell lung cancer in the US
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Fixed-duration CALQUENCE® (acalabrutinib) plus venetoclax, with or without obinutuzumab, significantly improved progression-free survival in 1st-line chronic lymphocytic leukemia in AMPLIFY Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca’s H1 and Q2 2024 Financial Results
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    CALQUENCE® (acalabrutinib) plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    FARXIGA approved in the US for the treatment of pediatric type-2 diabetes
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca furthers ambition to transform outcomes in early lung cancer and ​redefine metastatic breast cancer treatment at ASCO 2024​
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    New data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
    From AstraZeneca
    Via Business Wire
    Tickers AZN
    < Previous 1 2 3 4 5 6 7 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.